Mazar Andrew Paul 4
4 · ACTUATE THERAPEUTICS, INC. · Filed Apr 1, 2026
Research Summary
AI-generated summary of this filing
Actuate (ACTU) COO Andrew Mazar Receives 105,000-Share Award
What Happened
Andrew Mazar, Chief Operating Officer of Actuate Therapeutics (ACTU), received a grant of 105,000 derivative shares (reported as a $0.00 acquisition) on April 1, 2026. The award is a grant of options that do not require cash payment at grant; value will depend on future stock performance and vesting.
Key Details
- Transaction date: 2026-04-01; filing date: 2026-04-01 (timely filing).
- Grant: 105,000 derivative shares reported at $0.00 per share (reported as an award/grant).
- Vesting (per footnote): 25% vests on April 1, 2027; remaining 75% vests in equal monthly installments over the 36 months following the first anniversary.
- Shares owned after transaction: not specified in the provided filing details.
- No 10b5-1, tax-withholding, cashless exercise, or sale noted in the provided information.
Context
This is an equity compensation grant (stock options) intended for executive retention/incentive and is not an immediate market purchase or sale. Such awards vest over time and only convert to exercisable shares per the schedule above; they do not necessarily indicate near-term buying or selling by the insider.
Insider Transaction Report
- Award
Employee Stock Option (right to buy)
[F1]2026-04-01+105,000→ 105,000 totalExercise: $2.49Exp: 2036-04-01→ Common Stock (105,000 underlying)
Footnotes (1)
- [F1]Options will vest as to 25% on April 1, 2027 with the remaining 75% vesting in equal monthly installments during the 36 months following the first anniversary of the grant date.